Abstract
Objectives Sleep disorders are a global issue, and supplements for sleep and new devices for daily sleep status assessment are becoming widely available. Gamma-aminobutyric acid (GABA) and L-theanine are commonly used dietary supplements to improve sleep. This study examined whether the combined GABA (700 mg/day) and L-theanine (200 mg/day) intake improve sleep in adults with sleep problems and whether the Fitbit Charge 5 can detect sleep status changes the supplements induced.
Methods Participants received the supplements for four weeks, and changes in sleep quality measured using the Pittsburgh Sleep Quality Index (PSQI) and sleep-related data measured by the Fitbit Charge 5 were evaluated before and after the intake of the supplements.
Results Results obtained from 19 participants indicated significant improvement in the total PSQI score (9.42 ± 1.80 to 6.26 ± 1.66 (mean ± standard deviation), p<0.001). Sleep score improvement was insignificant for the Fitbit data(N=17). However, sleep recovery scores improved significantly (p=0.042). In addition, heart rate during sleep decreased with a significant difference of 1.3 bpm decrease in the first week of intake (p = 0.045).
Conclusions The simultaneous intake of GABA and L-theanine improved sleep in adults, and the Fitbit Charge 5 could detect improvements in objective information regarding sleep status.
Competing Interest Statement
This study was funded by Nestlé Health Science Company, Nestlé Japan Ltd. Yukikazu Kamada is an employee of Nestlé Health Science Company.
Clinical Trial
UMIN Study ID: UMIN000050613
Funding Statement
This study was funded by the Nestlé Health Science Company, Nestlé Japan Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted according to the Declaration of Helsinki and approved by the Institutional Review Board of Brain Care Clinic (BCC230203-2, date of approval: February 3, 2023)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All relevant data are presented in this manuscript. All the data are available from the authors upon request.
